WSI Co

WSI Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of WSI Co (299170.KQ) as of Oct 16, 2026 is 54.60. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 15.77 — a change of 246.32% (higher).

EV/FCF

54.60

YoY

246.32%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of WSI Co is 2025 54.60 . EV/FCF (Enterprise Value to Free Cash Flow) of WSI Co was 2024 15.77 . It decreases by 246.32% higher compared to the previous year.

The WSI Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-2,089.28 KRW
Jan 1, 2019
49.99 KRW
Jan 1, 2020
-297.31 KRW
Jan 1, 2021
34.32 KRW
Jan 1, 2022
-17.57 KRW
Jan 1, 2023
-10.43 KRW
Jan 1, 2024
15.77 KRW
Jan 1, 2025
54.60 KRW
The WSI Co EV/FCF history
YEAREV/FCFYoY
54.60+246.32%
15.77-251.11%
-10.43-40.62%
-17.57-151.19%
34.32-111.54%
-297.31-694.70%
49.99-102.39%
-2,089.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WSI Co Stock analysis

What does WSI Co do? WSI Co Ltd is a South Korean company operating in the health care sector, headquartered in Seoul. The company went public on September 21, 2018, with a ticker symbol of 299170.KQ and ISIN KR7299170001. WSI Co Ltd manufactures medical devices and pharmaceutical products, focusing on specific therapeutic areas. The company distributes a topical hemostatic agent called Flosils. It also supplies endoscopes used in spinal surgery, anti-adhesion agents, and bone hemostatic agents. WSI Co Ltd's business activities are centered around medical devices and pharmaceuticals, with an emphasis on products that address hemostasis and surgical procedures. The company's website is https://wsi-healthcare.com/, where further information about its products and services may be found. As a publicly listed company, WSI Co Ltd operates within the South Korean financial market and serves customers primarily in the health care industry. The company's product portfolio includes both medical devices and pharmaceuticals, targeting specific clinical applications such as surgical hemostasis and spinal procedures. There is no indication of additional product lines or services beyond those mentioned in the source description. The company's operations are based in Seoul, South Korea, and it has been publicly traded since 2018. WSI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WSI Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of WSI Co is 54.60 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of WSI Co changed from 15.77 to 54.60, representing a 246.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) WSI Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s WSI Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — WSI Co

All Key Metrics — WSI Co